ID   MYO1C_HUMAN             Reviewed;        1063 AA.
AC   O00159; Q4LE56; Q6NVJ7; Q86Y95;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 4.
DT   28-JUN-2023, entry version 220.
DE   RecName: Full=Unconventional myosin-Ic;
DE   AltName: Full=Myosin I beta;
DE            Short=MMI-beta;
DE            Short=MMIb;
GN   Name=MYO1C;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANTS ILE-795 AND ARG-826.
RC   TISSUE=Kidney;
RX   PubMed=9119401; DOI=10.1006/geno.1996.4526;
RA   Crozet F., El-Amraoui A., Blanchard S., Lenoir M., Ripoll C., Vago P.,
RA   Hamel C., Fizames C., Levi-Acobas F., Depetris D., Mattei M.-G., Weil D.,
RA   Pujol R., Petit C.;
RT   "Cloning of the genes encoding two murine and human cochlear unconventional
RT   type I myosins.";
RL   Genomics 40:332-341(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS ILE-795
RP   AND ARG-826.
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS ILE-795
RP   AND ARG-826.
RA   Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M., Ohara R.,
RA   Okazaki N., Koga H., Nagase T., Ohara O.;
RT   "Preparation of a set of expression-ready clones of mammalian long cDNAs
RT   encoding large proteins by the ORF trap cloning method.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANTS
RP   ILE-795 AND ARG-826.
RC   TISSUE=Eye, and Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-206 (ISOFORM 3).
RC   TISSUE=Teratocarcinoma;
RA   Strausberg R.L.;
RL   Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   PROTEIN SEQUENCE OF 36-43; 92-98; 104-125; 133-146; 172-188; 198-209;
RP   255-269; 341-350; 357-396; 400-412; 562-568; 606-624; 633-643; 648-656;
RP   666-674; 715-734; 814-822; 827-841; 875-884; 886-894; 901-930; 937-956 AND
RP   988-1047, ACETYLATION AT MET-1 (ISOFORM 2), METHYLATION AT LYS-383, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RA   Bienvenut W.V., Calvo F.;
RL   Submitted (FEB-2008) to UniProtKB.
RN   [8]
RP   SUBCELLULAR LOCATION (ISOFORM 3).
RX   PubMed=16133118; DOI=10.1007/s00418-005-0042-8;
RA   Kysela K., Philimonenko A.A., Philimonenko V.V., Janacek J., Kahle M.,
RA   Hozak P.;
RT   "Nuclear distribution of actin and myosin I depends on transcriptional
RT   activity of the cell.";
RL   Histochem. Cell Biol. 124:347-358(2005).
RN   [9]
RP   INTERACTION WITH RPS6 AND ACTIN, AND SUBCELLULAR LOCATION (ISOFORM 3).
RX   PubMed=16877530; DOI=10.1096/fj.05-5278fje;
RA   Cisterna B., Necchi D., Prosperi E., Biggiogera M.;
RT   "Small ribosomal subunits associate with nuclear myosin and actin in
RT   transit to the nuclear pores.";
RL   FASEB J. 20:1901-1903(2006).
RN   [10]
RP   IDENTIFICATION IN THE B-WICH COMPLEX.
RX   PubMed=16603771; DOI=10.1074/jbc.m600233200;
RA   Cavellan E., Asp P., Percipalle P., Oestlund Farrants A.-K.;
RT   "The WSTF-SNF2h chromatin remodeling complex interacts with several nuclear
RT   proteins in transcription.";
RL   J. Biol. Chem. 281:16264-16271(2006).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-408, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-408, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   ALTERNATIVE SPLICING (ISOFORM 1), AND SUBCELLULAR LOCATION (ISOFORM 1).
RX   PubMed=22736583; DOI=10.1002/cm.21040;
RA   Ihnatovych I., Migocka-Patrzalek M., Dukh M., Hofmann W.A.;
RT   "Identification and characterization of a novel myosin Ic isoform that
RT   localizes to the nucleus.";
RL   Cytoskeleton 69:555-565(2012).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1 (ISOFORM 2), AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-408, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [19]
RP   INTERACTION WITH SH3BGRL3, AND SUBCELLULAR LOCATION.
RX   PubMed=34380438; DOI=10.1186/s12860-021-00379-1;
RA   Di Pisa F., Pesenti E., Bono M., Mazzarello A.N., Bernardi C.,
RA   Lisanti M.P., Renzone G., Scaloni A., Ciccone E., Fais F., Bruno S.,
RA   Scartezzini P., Ghiotto F.;
RT   "SH3BGRL3 binds to myosin 1c in a calcium dependent manner and modulates
RT   migration in the MDA-MB-231 cell line.";
RL   BMC Mol. Cell Biol. 22:41-41(2021).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.74 ANGSTROMS) OF 36-760 (ISOFORM 2) IN COMPLEX
RP   WITH ADP ORTHOVANADATE AND CALM, INTERACTION WITH CALM AND YWHAB, FUNCTION,
RP   ACTIN-BINDING, FUNCTION IN ACTIN-DEPENDENT ATP HYDROLYSIS, AND MUTAGENESIS
RP   OF SER-736.
RX   PubMed=24636949; DOI=10.1016/j.jmb.2014.03.004;
RA   Stefan Munnich M.H., Manstein D.J.;
RT   "Crystal structure of human myosin 1c - the motor in GLUT4 exocytosis:
RT   implications for Ca(2+)-regulation and 14-3-3 binding.";
RL   J. Mol. Biol. 426:2070-2081(2014).
CC   -!- FUNCTION: Myosins are actin-based motor molecules with ATPase activity.
CC       Unconventional myosins serve in intracellular movements. Their highly
CC       divergent tails are presumed to bind to membranous compartments, which
CC       would be moved relative to actin filaments. Involved in glucose
CC       transporter recycling in response to insulin by regulating movement of
CC       intracellular GLUT4-containing vesicles to the plasma membrane.
CC       Component of the hair cell's (the sensory cells of the inner ear)
CC       adaptation-motor complex. Acts as a mediator of adaptation of
CC       mechanoelectrical transduction in stereocilia of vestibular hair cells.
CC       Binds phosphoinositides and links the actin cytoskeleton to cellular
CC       membranes. {ECO:0000269|PubMed:24636949}.
CC   -!- FUNCTION: [Isoform 3]: Involved in regulation of transcription.
CC       Associated with transcriptional active ribosomal genes. Appears to
CC       cooperate with the WICH chromatin-remodeling complex to facilitate
CC       transcription. Necessary for the formation of the first phosphodiester
CC       bond during transcription initiation. {ECO:0000250|UniProtKB:Q9WTI7}.
CC   -!- SUBUNIT: Interacts (via its IQ motifs) with CABP1 and CIB1; the
CC       interaction with CABP1 and CIB1 is calcium-dependent (By similarity).
CC       Interacts (via tail domain) with PLEKHB1 (via PH domain); the
CC       interaction is not affected by the presence or absence of calcium and
CC       CALM (By similarity). Interacts with POLR1A (By similarity). Interacts
CC       with POLR2A (By similarity). Component of the B-WICH complex, at least
CC       composed of SMARCA5/SNF2H, BAZ1B/WSTF, SF3B1, DEK, MYO1C, ERCC6,
CC       MYBBP1A and DDX21 (PubMed:16603771). Interacts (via its IQ motifs) with
CC       CALM; this precludes interaction with YWHAB (PubMed:24636949).
CC       Interacts with YWHAB; this precludes interaction with CALM
CC       (PubMed:24636949). Interacts with RPS6 (PubMed:16877530). Interacts
CC       with actin (PubMed:16877530). Interacts with LLPH (By similarity).
CC       Interacts with GLUT4 (By similarity). Interacts (via its IQ motifs)
CC       with SH3BGRL3; the interaction is dependent on calcium and takes place
CC       at membrane ruffles (PubMed:34380438). {ECO:0000250|UniProtKB:Q63355,
CC       ECO:0000250|UniProtKB:Q9WTI7, ECO:0000269|PubMed:16603771,
CC       ECO:0000269|PubMed:16877530, ECO:0000269|PubMed:24636949,
CC       ECO:0000269|PubMed:34380438}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:22736583}. Nucleus
CC       {ECO:0000269|PubMed:22736583}. Cytoplasm, cell cortex
CC       {ECO:0000250|UniProtKB:Q9WTI7}. Cell projection, stereocilium membrane
CC       {ECO:0000250|UniProtKB:Q92002}. Cytoplasmic vesicle
CC       {ECO:0000250|UniProtKB:Q9WTI7}. Cell projection, ruffle membrane
CC       {ECO:0000269|PubMed:34380438}. Note=Colocalizes with CABP1 and CIB1 at
CC       cell margin, membrane ruffles and punctate regions on the cell membrane
CC       (By similarity). Colocalizes in adipocytes with GLUT4 at actin-based
CC       membranes (By similarity). Colocalizes with GLUT4 at insulin-induced
CC       ruffles at the cell membrane (By similarity). Localizes transiently at
CC       cell membrane to region known to be enriched in PIP2 (By similarity).
CC       Activation of phospholipase C results in its redistribution to the
CC       cytoplasm (By similarity). Colocalizes with RNA polymerase II
CC       (PubMed:22736583). Translocates to nuclear speckles upon exposure to
CC       inhibitors of RNA polymerase II transcription (PubMed:22736583).
CC       {ECO:0000250|UniProtKB:Q9WTI7, ECO:0000269|PubMed:22736583}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus, nucleoplasm
CC       {ECO:0000269|PubMed:16133118}. Nucleus, nucleolus
CC       {ECO:0000269|PubMed:16133118, ECO:0000269|PubMed:16877530}.
CC       Note=Colocalizes with RNA polymerase II in the nucleus (By similarity).
CC       Colocalizes with RNA polymerase I in nucleoli (By similarity). In the
CC       nucleolus, is localized predominantly in dense fibrillar component
CC       (DFC) and in granular component (GC) (PubMed:16133118,
CC       PubMed:16877530). Accumulates strongly in DFC and GC during activation
CC       of transcription (PubMed:16133118). Colocalizes with transcription
CC       sites (By similarity). Colocalizes in the granular cortex at the
CC       periphery of the nucleolus with RPS6 (PubMed:16877530). Colocalizes in
CC       nucleoplasm with RPS6 and actin that are in contact with RNP particles
CC       (PubMed:16877530). Colocalizes with RPS6 at the nuclear pore level
CC       (PubMed:16877530). {ECO:0000250|UniProtKB:Q9WTI7,
CC       ECO:0000269|PubMed:16133118, ECO:0000269|PubMed:16877530}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=A;
CC         IsoId=O00159-1; Sequence=Displayed;
CC       Name=2; Synonyms=C;
CC         IsoId=O00159-2; Sequence=VSP_036861;
CC       Name=3; Synonyms=B, Nuclear myosin 1, NM1, NMI;
CC         IsoId=O00159-3; Sequence=VSP_036862;
CC   -!- DOMAIN: Binds directly to large unilamellar vesicles (LUVs) containing
CC       phosphatidylinositol 4,5-bisphosphate (PIP2) or inositol 1,4,5-
CC       trisphosphate (InsP3). The PIP2-binding site corresponds to the myosin
CC       tail domain (PH-like) present in its tail domain (By similarity).
CC       {ECO:0000250|UniProtKB:Q9WTI7}.
CC   -!- PTM: Isoform 2 contains a N-acetylmethionine at position 1.
CC   -!- SIMILARITY: Belongs to the TRAFAC class myosin-kinesin ATPase
CC       superfamily. Myosin family. {ECO:0000305}.
CC   -!- CAUTION: Represents an unconventional myosin. This protein should not
CC       be confused with the conventional myosin-1 (MYH1). {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH68013.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAE06097.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAF85599.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X98507; CAA67131.1; -; mRNA.
DR   EMBL; AK292910; BAF85599.1; ALT_INIT; mRNA.
DR   EMBL; AB210015; BAE06097.1; ALT_INIT; mRNA.
DR   EMBL; AC100748; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC044891; AAH44891.2; -; mRNA.
DR   EMBL; BC068013; AAH68013.1; ALT_INIT; mRNA.
DR   EMBL; BU855623; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS11003.1; -. [O00159-2]
DR   CCDS; CCDS42226.1; -. [O00159-1]
DR   CCDS; CCDS45562.1; -. [O00159-3]
DR   PIR; A59253; A59253.
DR   RefSeq; NP_001074248.1; NM_001080779.1. [O00159-1]
DR   RefSeq; NP_001074419.1; NM_001080950.1. [O00159-3]
DR   RefSeq; NP_203693.3; NM_033375.4. [O00159-2]
DR   PDB; 4BYF; X-ray; 2.74 A; A/C=36-760.
DR   PDBsum; 4BYF; -.
DR   AlphaFoldDB; O00159; -.
DR   SMR; O00159; -.
DR   BioGRID; 110725; 391.
DR   ComplexPortal; CPX-1099; B-WICH chromatin remodelling complex. [O00159-3]
DR   CORUM; O00159; -.
DR   DIP; DIP-33109N; -.
DR   IntAct; O00159; 217.
DR   MINT; O00159; -.
DR   STRING; 9606.ENSP00000352834; -.
DR   TCDB; 1.I.1.1.3; the nuclear pore complex (npc) family.
DR   GlyGen; O00159; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O00159; -.
DR   PhosphoSitePlus; O00159; -.
DR   SwissPalm; O00159; -.
DR   BioMuta; MYO1C; -.
DR   EPD; O00159; -.
DR   jPOST; O00159; -.
DR   MassIVE; O00159; -.
DR   MaxQB; O00159; -.
DR   PaxDb; O00159; -.
DR   PeptideAtlas; O00159; -.
DR   ProteomicsDB; 47744; -. [O00159-1]
DR   ProteomicsDB; 47745; -. [O00159-2]
DR   ProteomicsDB; 47746; -. [O00159-3]
DR   Antibodypedia; 953; 200 antibodies from 27 providers.
DR   DNASU; 4641; -.
DR   Ensembl; ENST00000361007.7; ENSP00000354283.2; ENSG00000197879.17. [O00159-2]
DR   Ensembl; ENST00000570984.7; ENSP00000459271.3; ENSG00000197879.17. [O00159-2]
DR   Ensembl; ENST00000575158.5; ENSP00000459174.1; ENSG00000197879.17. [O00159-2]
DR   Ensembl; ENST00000646049.1; ENSP00000493973.1; ENSG00000197879.17. [O00159-2]
DR   Ensembl; ENST00000648446.1; ENSP00000496799.1; ENSG00000197879.17. [O00159-3]
DR   Ensembl; ENST00000648651.1; ENSP00000496954.1; ENSG00000197879.17. [O00159-1]
DR   GeneID; 4641; -.
DR   KEGG; hsa:4641; -.
DR   MANE-Select; ENST00000648651.1; ENSP00000496954.1; NM_001080779.2; NP_001074248.1.
DR   UCSC; uc002fsn.4; human. [O00159-1]
DR   AGR; HGNC:7597; -.
DR   CTD; 4641; -.
DR   DisGeNET; 4641; -.
DR   GeneCards; MYO1C; -.
DR   HGNC; HGNC:7597; MYO1C.
DR   HPA; ENSG00000197879; Low tissue specificity.
DR   MalaCards; MYO1C; -.
DR   MIM; 606538; gene.
DR   neXtProt; NX_O00159; -.
DR   OpenTargets; ENSG00000197879; -.
DR   Orphanet; 90635; Autosomal dominant non-syndromic sensorineural deafness type DFNA.
DR   PharmGKB; PA31399; -.
DR   VEuPathDB; HostDB:ENSG00000197879; -.
DR   eggNOG; KOG0164; Eukaryota.
DR   GeneTree; ENSGT00940000157915; -.
DR   HOGENOM; CLU_000192_7_7_1; -.
DR   InParanoid; O00159; -.
DR   OMA; FICRGNC; -.
DR   OrthoDB; 1094820at2759; -.
DR   PhylomeDB; O00159; -.
DR   TreeFam; TF312960; -.
DR   PathwayCommons; O00159; -.
DR   Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-5250924; B-WICH complex positively regulates rRNA expression. [O00159-3]
DR   Reactome; R-HSA-9662360; Sensory processing of sound by inner hair cells of the cochlea.
DR   Reactome; R-HSA-9662361; Sensory processing of sound by outer hair cells of the cochlea.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   SignaLink; O00159; -.
DR   SIGNOR; O00159; -.
DR   BioGRID-ORCS; 4641; 17 hits in 1164 CRISPR screens.
DR   ChiTaRS; MYO1C; human.
DR   GeneWiki; MYO1C; -.
DR   GenomeRNAi; 4641; -.
DR   Pharos; O00159; Tbio.
DR   PRO; PR:O00159; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; O00159; protein.
DR   Bgee; ENSG00000197879; Expressed in right lung and 208 other tissues.
DR   ExpressionAtlas; O00159; baseline and differential.
DR   Genevisible; O00159; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IBA:GO_Central.
DR   GO; GO:0110016; C:B-WICH complex; IDA:ComplexPortal.
DR   GO; GO:0009925; C:basal plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005903; C:brush border; IEA:Ensembl.
DR   GO; GO:0005938; C:cell cortex; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0031941; C:filamentous actin; IDA:UniProtKB.
DR   GO; GO:0016328; C:lateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005902; C:microvillus; IDA:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; NAS:ComplexPortal.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0045335; C:phagocytic vesicle; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0060171; C:stereocilium membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016461; C:unconventional myosin complex; TAS:UniProtKB.
DR   GO; GO:0031982; C:vesicle; IBA:GO_Central.
DR   GO; GO:0051015; F:actin filament binding; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0003774; F:cytoskeletal motor activity; IEA:InterPro.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB.
DR   GO; GO:0031267; F:small GTPase binding; IPI:UniProtKB.
DR   GO; GO:0007015; P:actin filament organization; IBA:GO_Central.
DR   GO; GO:0071346; P:cellular response to type II interferon; IEA:Ensembl.
DR   GO; GO:0006338; P:chromatin remodeling; NAS:ComplexPortal.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0038089; P:positive regulation of cell migration by vascular endothelial growth factor signaling pathway; IMP:UniProtKB.
DR   GO; GO:1900078; P:positive regulation of cellular response to insulin stimulus; IEA:Ensembl.
DR   GO; GO:0035066; P:positive regulation of histone acetylation; NAS:ComplexPortal.
DR   GO; GO:0090314; P:positive regulation of protein targeting to membrane; IMP:UniProtKB.
DR   GO; GO:0045943; P:positive regulation of transcription by RNA polymerase I; NAS:ComplexPortal.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; NAS:ComplexPortal.
DR   GO; GO:0045945; P:positive regulation of transcription by RNA polymerase III; IDA:ComplexPortal.
DR   GO; GO:1900748; P:positive regulation of vascular endothelial growth factor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006612; P:protein targeting to membrane; IDA:UniProtKB.
DR   GO; GO:2000810; P:regulation of bicellular tight junction assembly; IMP:UniProtKB.
DR   GO; GO:0030050; P:vesicle transport along actin filament; IBA:GO_Central.
DR   CDD; cd01378; MYSc_Myo1; 1.
DR   Gene3D; 1.10.10.820; -; 1.
DR   Gene3D; 1.20.5.190; -; 1.
DR   Gene3D; 1.20.58.530; -; 1.
DR   Gene3D; 6.20.240.20; -; 1.
DR   Gene3D; 3.40.850.10; Kinesin motor domain; 1.
DR   Gene3D; 1.20.120.720; Myosin VI head, motor domain, U50 subdomain; 1.
DR   InterPro; IPR000048; IQ_motif_EF-hand-BS.
DR   InterPro; IPR036961; Kinesin_motor_dom_sf.
DR   InterPro; IPR001609; Myosin_head_motor_dom.
DR   InterPro; IPR010926; Myosin_TH1.
DR   InterPro; IPR036072; MYSc_Myo1.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR13140; MYOSIN; 1.
DR   PANTHER; PTHR13140:SF255; UNCONVENTIONAL MYOSIN-IC; 1.
DR   Pfam; PF00612; IQ; 2.
DR   Pfam; PF00063; Myosin_head; 1.
DR   Pfam; PF06017; Myosin_TH1; 1.
DR   PRINTS; PR00193; MYOSINHEAVY.
DR   SMART; SM00015; IQ; 3.
DR   SMART; SM00242; MYSc; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS50096; IQ; 2.
DR   PROSITE; PS51456; MYOSIN_MOTOR; 1.
DR   PROSITE; PS51757; TH1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Actin-binding; Alternative splicing;
KW   ATP-binding; Calmodulin-binding; Cell membrane; Cell projection; Cytoplasm;
KW   Cytoplasmic vesicle; Direct protein sequencing; Membrane; Methylation;
KW   Motor protein; Myosin; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat.
FT   CHAIN           1..1063
FT                   /note="Unconventional myosin-Ic"
FT                   /id="PRO_0000123445"
FT   DOMAIN          47..731
FT                   /note="Myosin motor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00782"
FT   DOMAIN          734..757
FT                   /note="IQ 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00116"
FT   DOMAIN          758..786
FT                   /note="IQ 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00116"
FT   DOMAIN          885..1059
FT                   /note="TH1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01093"
FT   REGION          608..630
FT                   /note="Actin-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00782"
FT   BINDING         88
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         96
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         139..148
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         192..196
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         383
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|Ref.7"
FT   MOD_RES         408
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         486
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WTI7"
FT   MOD_RES         536
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63355"
FT   MOD_RES         864
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63355"
FT   MOD_RES         1041
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63355"
FT   VAR_SEQ         1..35
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9119401"
FT                   /id="VSP_036861"
FT   VAR_SEQ         1..25
FT                   /note="MALQVELVPTGEIIRVVHPHRPCKL -> MRYRAS (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_036862"
FT   VARIANT         795
FT                   /note="V -> I (in dbSNP:rs8081370)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:9119401,
FT                   ECO:0000269|Ref.3"
FT                   /id="VAR_054855"
FT   VARIANT         826
FT                   /note="Q -> R (in dbSNP:rs9905106)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:9119401,
FT                   ECO:0000269|Ref.3"
FT                   /id="VAR_054856"
FT   MUTAGEN         736
FT                   /note="S->A: Abolishes interaction with YWHAB."
FT                   /evidence="ECO:0000269|PubMed:24636949"
FT   MUTAGEN         736
FT                   /note="S->E: Increases affinity for YWHAB."
FT                   /evidence="ECO:0000269|PubMed:24636949"
FT   CONFLICT        37
FT                   /note="E -> D (in Ref. 1; CAA67131)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        152
FT                   /note="R -> K (in Ref. 1; CAA67131)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        165
FT                   /note="E -> Q (in Ref. 1; CAA67131)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        200
FT                   /note="K -> E (in Ref. 6; BU855623)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        324
FT                   /note="E -> D (in Ref. 1; CAA67131)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        379
FT                   /note="D -> N (in Ref. 1; CAA67131)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        453
FT                   /note="T -> P (in Ref. 1; CAA67131)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        832
FT                   /note="S -> Y (in Ref. 1; CAA67131)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        986
FT                   /note="N -> I (in Ref. 1; CAA67131)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1062
FT                   /note="S -> Y (in Ref. 1; CAA67131)"
FT                   /evidence="ECO:0000305"
FT   HELIX           51..53
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           60..72
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          77..80
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          83..87
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           98..104
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           109..111
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           116..129
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          134..139
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           146..160
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           170..185
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          193..196
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          198..206
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          212..220
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           225..227
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           238..246
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           249..254
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           261..263
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   TURN            265..267
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          269..271
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           280..293
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           298..316
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           333..342
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           346..354
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          355..357
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          366..368
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           371..401
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          408..413
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          415..421
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          429..431
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           433..453
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           455..464
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           477..484
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   TURN            486..488
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           490..496
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          499..503
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           506..516
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          528..530
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          535..537
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          539..546
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          549..554
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           558..562
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           568..575
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           580..585
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           600..616
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          618..626
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           639..649
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           651..660
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          663..667
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           668..675
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           676..678
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          682..684
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           690..701
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          707..710
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   STRAND          712..718
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   HELIX           720..753
FT                   /evidence="ECO:0007829|PDB:4BYF"
FT   MOD_RES         O00159-2:1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
SQ   SEQUENCE   1063 AA;  121682 MW;  B105197BA07317B8 CRC64;
     MALQVELVPT GEIIRVVHPH RPCKLALGSD GVRVTMESAL TARDRVGVQD FVLLENFTSE
     AAFIENLRRR FRENLIYTYI GPVLVSVNPY RDLQIYSRQH MERYRGVSFY EVPPHLFAVA
     DTVYRALRTE RRDQAVMISG ESGAGKTEAT KRLLQFYAET CPAPERGGAV RDRLLQSNPV
     LEAFGNAKTL RNDNSSRFGK YMDVQFDFKG APVGGHILSY LLEKSRVVHQ NHGERNFHIF
     YQLLEGGEEE TLRRLGLERN PQSYLYLVKG QCAKVSSIND KSDWKVVRKA LTVIDFTEDE
     VEDLLSIVAS VLHLGNIHFA ANEESNAQVT TENQLKYLTR LLSVEGSTLR EALTHRKIIA
     KGEELLSPLN LEQAAYARDA LAKAVYSRTF TWLVGKINRS LASKDVESPS WRSTTVLGLL
     DIYGFEVFQH NSFEQFCINY CNEKLQQLFI ELTLKSEQEE YEAEGIAWEP VQYFNNKIIC
     DLVEEKFKGI ISILDEECLR PGEATDLTFL EKLEDTVKHH PHFLTHKLAD QRTRKSLGRG
     EFRLLHYAGE VTYSVTGFLD KNNDLLFRNL KETMCSSKNP IMSQCFDRSE LSDKKRPETV
     ATQFKMSLLQ LVEILQSKEP AYVRCIKPND AKQPGRFDEV LIRHQVKYLG LLENLRVRRA
     GFAYRRKYEA FLQRYKSLCP ETWPTWAGRP QDGVAVLVRH LGYKPEEYKM GRTKIFIRFP
     KTLFATEDAL EVRRQSLATK IQAAWRGFHW RQKFLRVKRS AICIQSWWRG TLGRRKAAKR
     KWAAQTIRRL IRGFVLRHAP RCPENAFFLD HVRTSFLLNL RRQLPQNVLD TSWPTPPPAL
     REASELLREL CIKNMVWKYC RSISPEWKQQ LQQKAVASEI FKGKKDNYPQ SVPRLFISTR
     LGTDEISPRV LQALGSEPIQ YAVPVVKYDR KGYKPRSRQL LLTPNAVVIV EDAKVKQRID
     YANLTGISVS SLSDSLFVLH VQRADNKQKG DVVLQSDHVI ETLTKTALSA NRVNSININQ
     GSITFAGGPG RDGTIDFTPG SELLITKAKN GHLAVVAPRL NSR
//
